SEC Tracker
Get the app

Interpace Biosciences IDXG

Interpace Biosciences reports Q3 2026 revenue range

Securities offering

Form
FWP
Filed
Importance
Routine
  1. Q3 2026 revenue expected between $10.1M and $10.4M
  2. QoQ growth of 11% to 14% compared to Q2 2026
  3. YoY growth of 15% to 18% compared to Q3 2025

Written from the FWP on EDGAR. Check the filing before you rely on it.

Open in the appGet the appView on EDGAR

Get an email when Interpace Biosciences files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 3841 and related industry codes: the same peer list as the financial tables.

  1. Global Innovative Platforms GIPL public float $3M, Sep 30, 2025
  2. ENDRA Life Sciences NDRA public float $3M, Jun 30, 2025
  3. Bluejay Diagnostics BJDX public float $3M, Jun 30, 2025
  4. Stimcell Energetics STME public float $2M, Nov 30, 2025
  5. LogicMark LGMK public float $2M, Jun 30, 2025